Kevin D. Cooper, MD joined Case Western Reserve University and University Hospitals Cleveland Medical Center in 1995 from prior positions at the University of Michigan and the National Institutes of Health, following training at Oregon Health Sciences University and the University of Florida. He has developed a highly matrixed department that intersects ten geographical clinical dermatology practice sites with QI teaching, skin biology-specific research cores, and a complementary portfolio of research programs that span basic laboratory, translational, and clinical trial investigations. With interests in inflammatory-mediated skin diseases, lymphoma, and photomedicine/photoimmunology, Dr. Cooper has been continuously federally funded since 1986 and has published over 300 papers and chapters. He enjoys mentoring faculty, residents, fellows, and students across each of these dimensions.
Dr. Cooper is professor and chair of the Department of Dermatology at both Case Western Reserve University (CWRU) School of Medicine and University Hospitals C Medical Center (UHCMC). He is also staff physician for the Dermatology Service at the Cleveland VA Hospital. Dr. Cooper is the Director of the NIAMS Skin Diseases Research Center at CWRU, focusing on creating advances in skin diseases, and the Director of the Murdough Family Center for Psoriasis. Dr. Cooper is a co-inventor of the first biologic to be FDA-approved for psoriasis, and he is a co-founder of Fluence Therapeutics, a start-up biomedical company created to develop a novel photodynamic therapy for psoriasis and lymphoma. He enjoys consulting in the early phases of product development for skin care and pharmaceuticals. Dr. Cooper is past President of the Society for Investigative Dermatology and the Association of Professors of Dermatology.
I investigate psoriasis, atopic dermatitis, autoimmunity, cutaneous immunobiology, UV and solar effects, and immunomodulatory therapy.